FGP
NTLA icon

Freestone Grove Partners’s Intellia Therapeutics NTLA Stock Holding History

Freestone Grove Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.1K Buy
+1,958
New +$27.4K ﹤0.01% 878
2026
Q1 		– Sell
-88,406
Closed -$795K – 1121
2025
Q4 		$795K Buy
+88,406
New +$1.22M 0.01% 493

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Freestone Grove Partners's NTLA Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 1,958 shares worth $33.1K. The stake represents ﹤0.01% of the portfolio and ranks #878 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in NTLA as recently as Q4 2025.

Freestone Grove Partners first reported a position in NTLA in Q4 2025 and has held it in 2 quarters since. The position peaked at $795K in Q4 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Freestone Grove Partners held 1,958 shares of Intellia Therapeutics worth $33.1K as of Q2 2026.
  • Intellia Therapeutics was a new Freestone Grove Partners position in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #878 holding.
  • Freestone Grove Partners first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Freestone Grove Partners's Intellia Therapeutics position peaked at $795K in Q4 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.